ANIX
Anixa Biosciences Inc
2.70$
-2.5%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +3.1% | -39.7% | +56.6% | -26.8% | -2.4% | +50.2% | +283.6% | -16.1% | -16.1% | -15.4% | -25.5% | |
| – | +9.1% | -50.7% | +106.3% | -21.0% | +10.0% | +53.8% | +284.3% | -16.1% | -16.0% | -15.8% | -25.6% | |
| – | +30.0% | -43.0% | +34.2% | -8.5% | +14.3% | +83.8% | +353.9% | -57.6% | -92.6% | +38.9% | -2.1% | |
| – | +15.5% | -52.2% | +111.2% | -26.1% | +15.5% | +55.0% | +294.5% | -16.9% | -19.7% | -16.4% | -23.8% | |
| – | – | – | – | – | -78.3% | -96.6% | – | – | +487.0% | -35.9% | -100.0% | |
| – | – | – | – | – | -235,000,100.0% | – | – | – | – | – | – | |
| – | +265.9% | +260.5% | -66.4% | +37.9% | +176.0% | -72.9% | +367.3% | -16.5% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -12.0% | -13.6% | -15.7% | -52.0% | – | – | – | – | – | – | – | |
| – | -15.1% | +8.4% | -80.8% | +42.2% | +17.1% | -19.8% | +25.4% | +48.4% | -2.8% | +25.7% | -21.2% | |
| – | -67.2% | -21.1% | +89.8% | +42.2% | +17.1% | -19.8% | +6.8% | +60.4% | -0.4% | +23.3% | -21.3% | |
| – | – | – | – | – | – | – | -29.3% | +17.9% | +13.0% | -44.2% | +41.4% | |
| – | -30.6% | -0.4% | +28.7% | +21.2% | +0.7% | -60.3% | -41.5% | +94.9% | -22.3% | +154.9% | -68.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +26.0% | -80.5% | +702.3% | -31.4% | -3.7% | +67.3% | +304.5% | -18.0% | -16.2% | -17.8% | -24.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.6% | -9.2% | +39.6% | +44.5% | +12.3% | +12.3% | +28.6% | +6.3% | +2.0% | +3.0% | +1.7% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.